Melanoma Immunotherapy: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Melanoma Immunotherapy

Melanoma Immunotherapy represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Melanoma Immunotherapy Recommended?

• Unresectable Stage III or Stage IV metastatic melanoma of cutaneous, acral, or mucosal origin.

• High-risk resected Stage III melanoma requiring adjuvant Pembrolizumab or Nivolumab immunotherapy.

• BRAF V600E/K mutation-positive metastatic melanoma requiring targeted BRAF/MEK inhibitor therapy.

• Patients experiencing disease progression on prior single-agent immunotherapy.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: Pathology & Molecular Staging

Dermatopathology review, Breslow depth measurement, and NGS / PCR testing for BRAF, NRAS, and c-KIT mutations.

Step 2: Personalized Protocol Selection

Selection of dual immunotherapy (Nivo/Ipi) vs single-agent PD-1 vs oral BRAF/MEK targeted therapy.

Step 3: Daycare Immunotherapy Delivery

Outpatient intravenous infusion under specialized oncology nursing with vital signs monitoring.

Step 4: Periodic PET-CT Surveillance

Serial whole-body FDG PET-CT scans every 12 weeks to document sustained deep metabolic remissions.

Director's Signature Innovation: Advanced Melanoma Immunotherapy & Targeted Oncology

Dr. Neha Gupta delivers cutting-edge immunotherapy and precision targeted molecular therapy for advanced and metastatic cutaneous, acral, and mucosal melanoma. Combining dual immune checkpoint blockade (Nivolumab + Ipilimumab) or targeted BRAF/MEK kinase inhibitors (Dabrafenib + Trametinib, Encorafenib + Binimetinib for BRAF V600E/K positive tumors), metastatic melanoma has been transformed from a disease with limited life expectancy into one where over 50% of patients achieve long-term 5-year and 10-year overall survival and durable complete remission.

✔ Dual Immunotherapy (Nivo + Ipi): High 50%+ 5-year survival benchmark in advanced metastatic melanoma

✔ BRAF V600 Molecular Testing: Rapid molecular sequencing guiding oral targeted BRAF/MEK inhibitors

✔ Adjuvant Immunotherapy: Reduces recurrence risk by over 40% in resected high-risk Stage III melanoma

✔ Comprehensive Dermatological Surveillance: Digital dermoscopy and PET-CT monitoring for deep remissions

Recovery Timeline & Functional Milestones

Phase 1: Baseline Workup & First Cycle (Cycle 1 (Day 1))

BRAF mutation status check, baseline whole-body PET-CT, 30–60 minute outpatient infusion in Daycare suite.

Phase 2: Active Treatment Phase (Month 1 – 3)

3 to 4-weekly immunotherapy cycles, skin/endocrine toxicity monitoring, and clinical response check.

Phase 3: Response Evaluation (Month 3 – 6)

Restaging whole-body PET-CT scan assessing objective complete or partial metabolic response.

Phase 4: Long-Term Survivorship (Month 6 – Year 2)

Ongoing maintenance immunotherapy schedule achieving durable multi-year cancer-free survival.

Frequently Asked Clinical Questions (FAQs)

Why is immunotherapy the gold-standard treatment for melanoma?

Melanoma is one of the most immunogenic cancers known. Immunotherapy drugs (anti-PD-1 like Pembrolizumab/Nivolumab and anti-CTLA-4 like Ipilimumab) block the inhibitory signals that melanoma cells use to hide from immune T-cells, empowering your own white blood cells to aggressively locate and eradicate melanoma tumors throughout the body.

What is BRAF mutation testing and how does it change treatment?

Approximately 40–50% of melanomas have a mutation in the BRAF gene (BRAF V600E/K). If positive, patients can be treated with oral targeted tablets (like Dabrafenib + Trametinib) that block the mutant cancer growth pathway directly, causing rapid tumor shrinkage within days.

Is Melanoma Immunotherapy covered under Ayushman Bharat?

Yes, melanoma immunotherapy infusions, BRAF/MEK targeted therapies, PET-CT scans, and daycare admissions at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Melanoma Immunotherapy is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.